KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Deferred Taxes (2017 - 2019)

Amneal Pharmaceuticals (AMRX) has 3 years of Deferred Taxes data on record, last reported at $33000.0 in Q4 2019.

  • For Q4 2019, Deferred Taxes rose 110.06% year-over-year to $33000.0; the TTM value through Sep 2020 reached $33000.0, down 99.99%, while the annual FY2019 figure was $371.7 million, 4038.09% up from the prior year.
  • Deferred Taxes reached $33000.0 in Q4 2019 per AMRX's latest filing, down from $389.9 million in the prior quarter.
  • Across five years, Deferred Taxes topped out at $389.9 million in Q3 2019 and bottomed at -$14.5 million in Q2 2018.
  • Average Deferred Taxes over 3 years is $36.3 million, with a median of -$420000.0 recorded in 2018.
  • The widest YoY moves for Deferred Taxes: up 6528.56% in 2019, down 1830.47% in 2019.
  • A 3-year view of Deferred Taxes shows it stood at $1.3 million in 2017, then crashed by 125.71% to -$328000.0 in 2018, then surged by 110.06% to $33000.0 in 2019.
  • Per Business Quant database, its latest 3 readings for Deferred Taxes were $33000.0 in Q4 2019, $389.9 million in Q3 2019, and -$8.3 million in Q2 2019.